Regadenoson Patent Expiration
Regadenoson is Used for cardiac imaging and increasing coronary blood flow. It was first introduced by Astellas Pharma Us Inc
Regadenoson Patents
Given below is the list of patents protecting Regadenoson, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Lexiscan | US8106183 | Process for preparing an A2A-adenosine receptor agonist and its polymorphs | Feb 02, 2027 | Astellas |
| Lexiscan | US9085601 | Process for preparing an A2A-adenosine receptor agonist and its polymorphs | Feb 02, 2027 | Astellas |
| Lexiscan | USRE47301 | Process for preparing an A2A-adenosine receptor agonist and its polymorphs | Feb 02, 2027 | Astellas |
| Lexiscan | US6403567 | N-pyrazole A2A adenosine receptor agonists |
Apr 10, 2022
(Expired) | Astellas |
| Lexiscan | US6642210 | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US7144872 | N-pyrazole A2A receptor agonists |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US7183264 | N-pyrazole A2A receptor agonists |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US7582617 | Myocardial perfusion imaging method |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US7655636 | Use of A2A adenosine receptor agonists |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US7655637 | N-pyrazole A2A receptor agonists |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US7683037 | Myocardial perfusion imaging method |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US8106029 | Use of A2A adenosine receptor agonists |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US8133879 | Myocardial perfusion imaging methods and compositions |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US8183226 | Myocardial perfusion imaging method |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US8470801 | Myocardial perfusion imaging methods and compositions |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US8536150 | Methods of myocardial perfusion imaging |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US9045519 | N-pyrazole A2A receptor agonists |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | US9289446 | Myocardial perfusion imaging methods and compositions |
Jun 22, 2019
(Expired) | Astellas |
| Lexiscan | USRE47351 | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
Jun 22, 2019
(Expired) | Astellas |
Regadenoson's Family Patents
Explore Our Curated Drug Screens
Regadenoson Generic API Manufacturers
Several generic applications have been filed for Regadenoson. The first generic version for Regadenoson was by Accord Healthcare Inc and was approved on Apr 11, 2022. And the latest generic version is by Indies Pharma Jamaica Ltd and was approved on Aug 22, 2024.
Given below is the list of companies who have filed for Regadenoson generic, along with the locations of their manufacturing plants worldwide.
1. ACCORD HLTHCARE
Accord Healthcare Inc has filed for 1 generic for Regadenoson. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.4MG/5ML (0.08MG/ML) | solution | Prescription | INTRAVENOUS | AP | Apr 11, 2022 |
2. APOTEX
Apotex Inc has filed for 1 generic for Regadenoson. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.4MG/5ML (0.08MG/ML) | solution | Prescription | INTRAVENOUS | AP | Apr 11, 2022 |
Manufacturing Plant Locations New
Apotex's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Apotex as present at those locations.
| Country | City | Firm Name | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||
| Canada |
| |||||||||||||
| India |
| |||||||||||||
3. BAXTER HLTHCARE CORP
Baxter Healthcare Corp has filed for 1 generic for Regadenoson. Given below are the details of the strengths of this generic introduced by Baxter Hlthcare Corp.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.4MG/5ML (0.08MG/ML) | solution | Prescription | INTRAVENOUS | AP | May 23, 2023 |
4. DR REDDYS
Dr Reddys Laboratories Ltd has filed for 1 generic for Regadenoson. Given below are the details of the strengths of this generic introduced by Dr Reddys.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.4MG/5ML (0.08MG/ML) | solution | Prescription | INTRAVENOUS | AP | Apr 11, 2022 |
5. EUGIA PHARMA
Eugia Pharma Specialities Ltd has filed for 1 generic for Regadenoson. Given below are the details of the strengths of this generic introduced by Eugia Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.4MG/5ML (0.08MG/ML) | solution | Prescription | INTRAVENOUS | AP | Oct 26, 2022 |
Manufacturing Plant Locations New
Eugia Pharma's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Eugia Pharma as present at those locations.
| Country | City | Firm Name | ||||||
|---|---|---|---|---|---|---|---|---|
| India |
| |||||||
6. GE HEALTHCARE
Ge Healthcare has filed for 1 generic for Regadenoson. Given below are the details of the strengths of this generic introduced by Ge Healthcare.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.4MG/5ML (0.08MG/ML) | solution | Prescription | INTRAVENOUS | AP | Aug 5, 2024 |
Manufacturing Plant Locations New
Ge Healthcare's manufacturing plants are situated in 8 countries - United States, Norway, Austria, Finland, Ireland, Japan, United Kingdom, China. Given below are the details of these plant locations as well as the firm names of Ge Healthcare as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
| Norway |
| |||||||||||||||||
| Austria |
| |||||||||||||||||
| Finland |
| |||||||||||||||||
| Ireland |
| |||||||||||||||||
| Japan |
| |||||||||||||||||
| United Kingdom |
| |||||||||||||||||
| China |
| |||||||||||||||||
7. GLAND PHARMA LTD
Gland Pharma Ltd has filed for 1 generic for Regadenoson. Given below are the details of the strengths of this generic introduced by Gland Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.4MG/5ML (0.08MG/ML) | solution | Prescription | INTRAVENOUS | AP | Jul 12, 2022 |
8. HIKMA
Hikma Pharmaceuticals Usa Inc has filed for 1 generic for Regadenoson. Given below are the details of the strengths of this generic introduced by Hikma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.4MG/5ML (0.08MG/ML) | solution | Prescription | INTRAVENOUS | AP | Feb 2, 2023 |
Manufacturing Plant Locations New
Hikma's manufacturing plants are situated in 3 countries - United States, Portugal, Jordan. Given below are the details of these plant locations as well as the firm names of Hikma as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||
| Portugal |
| |||||||||
| Jordan |
| |||||||||
9. HOSPIRA
Hospira Inc has filed for 1 generic for Regadenoson. Given below are the details of the strengths of this generic introduced by Hospira.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.4MG/5ML (0.08MG/ML) | solution | Prescription | INTRAVENOUS | AP | Aug 31, 2022 |
Manufacturing Plant Locations New
Hospira's manufacturing plants are situated in 3 countries - Australia, United States, Dominican Republic (the). Given below are the details of these plant locations as well as the firm names of Hospira as present at those locations.
| Country | City | Firm Name | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Australia |
| |||||||||||||
| United States |
| |||||||||||||
| Dominican Republic (the) |
| |||||||||||||
10. IMS LTD
International Medication Systems Ltd has filed for 1 generic for Regadenoson. Given below are the details of the strengths of this generic introduced by Ims Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.4MG/5ML (0.08MG/ML) | solution | Prescription | INTRAVENOUS | AP | May 23, 2022 |
Manufacturing Plant Locations New
Ims Ltd's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Ims Ltd as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||
11. INDIES PHARMA
Indies Pharma Jamaica Ltd has filed for 1 generic for Regadenoson. Given below are the details of the strengths of this generic introduced by Indies Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.4MG/5ML (0.08MG/ML) | solution | Prescription | INTRAVENOUS | AP | Aug 22, 2024 |
12. MEITHEAL
Meitheal Pharmaceuticals Inc has filed for 1 generic for Regadenoson. Given below are the details of the strengths of this generic introduced by Meitheal.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.4MG/5ML (0.08MG/ML) | solution | Prescription | INTRAVENOUS | AP | Apr 11, 2022 |
13. MYLAN
Mylan Pharmaceuticals Inc has filed for 1 generic for Regadenoson. Given below are the details of the strengths of this generic introduced by Mylan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.4MG/5ML (0.08MG/ML) | solution | Prescription | INTRAVENOUS | AP | Apr 4, 2023 |
Manufacturing Plant Locations New
Mylan's manufacturing plants are situated in 4 countries - United States, India, Canada, Ireland. Given below are the details of these plant locations as well as the firm names of Mylan as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
| India |
| |||||||||||||||||
| Canada |
| |||||||||||||||||
| Ireland |
| |||||||||||||||||